IDE
IDE (insulin-degrading enzyme) is a zinc metallopeptidase of the peptidase M16 family that degrades intracellular insulin and thereby terminates its activity. It also breaks down other peptides, including glucagon, amylin, bradykinin and kallidin. Browse Assay Genie's current range of IDE research reagents below, or read on for the biology behind the target.
IDE is a zinc metallopeptidase that degrades intracellular insulin and so terminates insulin activity. It also takes part in intercellular peptide signalling by degrading a range of peptides, among them glucagon, amylin, bradykinin and kallidin. Its preferential affinity for insulin means that insulin can inhibit the degradation of other substrates, such as beta-amyloid, by the enzyme.
The IDE gene encodes a protein that belongs to the peptidase M16 family, listed by HGNC in the M16 metallopeptidases gene group, and assigned EC 3.4.24.56. The protein localises primarily to the cytoplasm, and UniProt records it in the cytosol, at the cell membrane and in secreted form. In some cell types it is also found in the extracellular space, peroxisome and mitochondrion. Alternative splicing gives multiple transcript variants that encode distinct isoforms; further variants have been described but not experimentally verified. Mouse and rat both carry an Ide ortholog.
IDE has relevance beyond peptide turnover. Deficiencies in its function are associated with Alzheimer's disease and type 2 diabetes mellitus, although mutations in the gene have not been shown to cause either disease. In microbial infection, the membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV). This combination of roles makes IDE a useful subject for studies of peptide clearance, metabolic regulation and host-virus interaction.
IDE degrades intracellular insulin and ends its activity, which makes it relevant to studies of insulin clearance and of glucagon and amylin turnover.
Insulin competes with beta-amyloid for degradation by IDE, and deficiencies in IDE function are associated with Alzheimer's disease.
Reduced IDE function is associated with type 2 diabetes mellitus, though gene mutations have not been shown to be causative.
The membrane-associated isoform of IDE serves as an entry receptor for varicella-zoster virus, supporting work on viral entry mechanisms.
IDE is a zinc metallopeptidase that degrades intracellular insulin, terminating its activity. It also degrades peptides such as glucagon, amylin, bradykinin and kallidin. Because it prefers insulin, insulin can inhibit its degradation of other substrates, including beta-amyloid.
The HGNC name is insulin degrading enzyme, and UniProt lists it as insulin-degrading enzyme; no other aliases are recorded. Alternative splicing produces multiple transcript variants encoding distinct isoforms, including a membrane-associated isoform that acts as a varicella-zoster virus entry receptor.
IDE deficiencies are associated with Alzheimer's disease and type 2 diabetes mellitus, but gene mutations have not been shown to cause them. Orthologs named Ide exist in mouse and rat. Check the datasheet of any product for its validated reactivity.
Peptide substrates of IDE and related targets in insulin signalling, metabolism and neurodegeneration research.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P14735; product specifications from Assay Genie datasheets.